Birth control pills Novinet, use, side effects, contraindications. "Novine": instructions for use. "Novinet": side effects, analogues, reviews Storage periods and conditions

The average prices for drugs of the same dosage dispensed from Russian pharmacies in 2019 are indicated. Share your experience of using Novinet

Is this medicine expensive?

Have you had any side effects with this medicine?

How to save money How to choose The analogues recommended in the table include drugs with the most suitable content of the active substance used in Novinet. For each of these drugs, average prices for the minimum volume are given, regularly updated taking into account market conditions. Novinet in different release forms may differ in price, this is normal. Substitutes with the same medicinal properties can be both more expensive and cheaper. Why are analogues more expensive or cheaper than Novinet? Usually, a lot of time and money are spent on the production of the chemical formula of a drug, and tests are carried out. The pharmaceutical company then buys the patent and makes it commercially available. The price of the drug is high because it is necessary to recoup the investment. Other medicines similar in composition, less well-known but time-tested, remain several times cheaper. How to spot a fake In order not to buy a counterfeit drug, you need to carefully look at your purchase.

Attention There are contraindications! Before replacing a particular drug, consult your doctor. Follow the dosage prescribed by your doctor! Medicines cannot be used later than the date indicated on their packaging.

Novinet: instructions for use and reviews

Novinet is a monophasic oral contraceptive.

Release form and composition

Dosage form – film-coated tablets: round, biconvex, light yellow in color, marked “RG” on one side, “P9” on the other (21 pieces in blisters, 1 or 3 blisters in a cardboard pack).

Ethinyl estradiol – 20 mcg;
Desogestrel – 150 mcg.

Auxiliary components: alpha-tocopherol, colloidal silicon dioxide, magnesium stearate, stearic acid, potato starch, povidone, lactose monohydrate, quinoline yellow dye (E104).

Film shell composition: hypromellose, macrogol 6000, propylene glycol.

Pharmacological properties

Pharmacodynamics

Novinet belongs to combined oral contraceptives. Its main contraceptive effect is to reduce the production of gonadotropins and suppress ovulation. Also, when used, the viscosity of the cervical mucus increases, which makes it difficult for sperm to move through the cervical canal, and the condition of the endometrium changes, as a result of which the fertilized egg does not implant into the uterine wall.

Ethinyl estradiol is a synthetic analogue of endogenous estradiol. Desogestrel is characterized by a pronounced gestagenic and antiestrogenic effect, reminiscent of that of endogenous progesterone, as well as minor anabolic and androgenic activity. Novinet has a beneficial effect on lipid metabolism: it increases the content of high-density lipoproteins in the blood plasma, without changing the concentration of low-density lipoproteins. During the use of the drug, there is a significant decrease in the amount of blood lost monthly during menstruation (with the initial diagnosis of menorrhagia), normalization of the menstrual cycle, and improvement in skin condition (especially in the presence of acne vulgaris).

Pharmacokinetics

When taken orally, desogestrel is almost completely and rapidly absorbed from the gastrointestinal tract. The biologically active metabolite of this compound is 3-keto-desogestrel. The average maximum level of desogestrel in the blood serum is 2 ng/ml and is recorded 1.5 hours after taking the tablet. The bioavailability of the substance is 62–81%.

3-keto-desogestrel binds to plasma proteins, mainly sex hormone-binding globulin and albumin. The volume of distribution is 1.5 l/kg.

In addition to 3-keto-desogestrel, which is formed in the intestinal wall and liver, other metabolites of desogestrel are known: 3β-OH-desogestrel, 3α-OH-desogestrel and 3α-OH-5α-H-desogestrel, which are first-phase metabolites. They are not characterized by pharmacological activity and partially, through conjugation (the second stage of metabolization), pass into the form of polar metabolites (glucuronates and sulfates). Clearance from blood plasma is approximately 2 ml/min per 1 kg of body weight.

The average half-life of 3-keto-desogestrel is 30 hours. Metabolites are excreted through the intestines and kidneys in a ratio of 6:4. A stable concentration of desogestrel in the body is observed in the second half of the cycle. During this period, the level of this substance increases 2-3 times.

Ethinyl estradiol is absorbed from the gastrointestinal tract quite quickly and completely. On average, the maximum concentration in the blood serum is 80 pg/ml and is achieved 1-2 hours after taking the tablet. Due to the “first pass” effect and presystemic conjugation, the bioavailability of the substance reaches 60%.

Ethinyl estradiol is 100% bound to plasma proteins, mainly albumin. The volume of distribution is 5 l/kg.

Presystemic conjugation of this compound is very significant. After passing through the intestinal wall (first phase of metabolism), ethinyl estradiol participates in the process of conjugation in the liver (second phase of metabolism). The substance and its conjugates, formed in the first phase of metabolism (glucuronides and sulfates), are excreted into bile and become elements of the enterohepatic circulation. The clearance of ethinyl estradiol from blood plasma is approximately 5 ml/min per 1 kg of body weight. Its average half-life is approximately 24 hours. About 60% of the substance is excreted through the intestines and about 40% through the kidneys.

A stable level of ethinyl estradiol in the body is established on the 3-4th day after starting Novinet. At the same time, the content of the substance in the blood serum is 30-40% higher than after taking a single dose.

Indications for use

The use of Novinet is indicated for women for oral contraception.

Contraindications

Angina pectoris, transient ischemic attack and other precursors of thrombosis (including when indicated in the anamnesis);
Moderate or severe arterial hypertension (blood pressure (BP) 160/100 mmHg or more) and other multiple and/or severe risk factors for arterial or venous thrombosis;
Migraine with focal neurological symptoms, including medical history;
History of venous thromboembolism;
Myocardial infarction, deep vein thrombosis of the leg, stroke, pulmonary embolism and other forms of venous or arterial thrombosis or thromboembolism, currently and in history;
Dyslipidemia;
Diabetes mellitus (with angiopathy);
Gallstone disease, including medical history;
Liver neoplasms, including medical history;
Severe liver diseases, cholestatic jaundice (including during pregnancy), hepatitis, including a history (before normalization of laboratory and functional parameters and within 3 months after it);
Pancreatitis (including medical history), occurring with severe hypertriglyceridemia;
Jaundice due to glucocorticosteroids (GCS);
Dubin-Johnson syndrome, Gilbert's syndrome, Rotor syndrome;
Severe skin itching, otosclerosis and its progression while taking GCS or during a previous pregnancy;
Vaginal bleeding of unknown origin;
Hormone-dependent malignant tumors of the mammary glands and genital organs or suspicions of them;
Breast-feeding;
The period of pregnancy, including suspicion of it;
Smoking more than 15 cigarettes per day over the age of 35;
Hypersensitivity to the components of the drug.

Caution should be exercised in women with conditions that increase the risk of developing arterial or venous thrombosis and thromboembolism: obesity (body weight index exceeds 30 kg/m2), smoking, age over 35 years, family history, dyslipoproteinemia, migraine, arterial hypertension, epilepsy, atrial fibrillation, valvular heart defects, ulcerative colitis, Crohn's disease, sickle cell anemia, chronic and acute liver pathologies, hypertriglyceridemia (including family history), prolonged immobilization, major surgery, surgery on the lower extremities, superficial thrombophlebitis, varicose veins, severe trauma, postpartum period, severe depression (including history), systemic lupus erythematosus (SLE), diabetes mellitus (without vascular complications), changes in biochemical parameters, including hyperhomocysteinemia, activated protein C resistance, antithrombin III and protein S or C deficiency , antiphospholipid antibodies, including antibodies to cardiolipin, lupus anticoagulant.

Instructions for use of Novinet: method and dosage

Novinet is taken for 21 days, starting from the first day of menstrual bleeding, 1 tablet orally at the same time of day. After taking all the tablets from the blister, take a 7-day break, during which menstrual-like bleeding occurs. Taking tablets from the next blister should be started the next day after the break, even if bleeding continues. This drug regimen provides contraceptive effect as long as it is needed.

If a woman starts taking the first pill on the first day of the menstrual cycle, additional contraceptive measures are not required. When starting use from the second to fifth day of menstruation in the first cycle, it is necessary to use barrier methods of contraception for the first 7 days. If more than 5 days have passed since the start of menstruation, you should not start taking pills in this cycle.

After childbirth, taking the drug can be started no earlier than 21 days without additional contraceptive measures, subject to prior consultation with a doctor and the absence of breastfeeding. If a woman had sexual contact during this period, the start of therapy should be postponed until the start of her first menstruation. If use is started more than 21 days after birth, barrier contraceptives should be used simultaneously for the first 7 days.

In the absence of contraindications, taking pills after an abortion should be started on the day of surgery without using additional contraceptive measures.

When switching from an oral hormonal contraceptive containing ethinyl estradiol 30 mcg and taken on a 21-day schedule, Novinet should be taken the next day after taking the last tablet of the previous contraceptive without a seven-day break and the use of additional contraception.

When switching from products containing 28 tablets, use of Novinet begins the next day after taking the last tablet from the package of the previous contraceptive.

After previous use of oral hormonal mini-pills containing only progestogen, it is recommended to start switching to Novinet on the 1st day of the cycle without the use of additional methods of contraception.

If there is no menstruation while taking the mini-pill, it is necessary to exclude the presence of pregnancy and only then switch to taking Novinet on any day of the menstrual cycle using additional methods of contraception during the first 7 days. As additional methods of contraception during this period, it is recommended to use a condom, a cervical cap with spermicidal gel, or sexual abstinence. It is not recommended to use the calendar method of protection during the first 7 days of taking the drug.

If a woman wants to postpone the onset of menstruation, then taking tablets from the next blister must be started immediately, according to the usual regimen, without taking a 7-day break. During this period, breakthrough or spotting bleeding may occur, which does not reduce the contraceptive effect of the drug. After the prescribed 7-day break, regular use of the drug is restored.

If you accidentally miss a dose at the scheduled time, you should take the pill as soon as you remember. If the delay period is less than 12 hours, the contraceptive effect of the drug is not impaired, further use can be continued as usual. A delay of more than 12 hours is considered a missed pill and violates the reliability of contraception in this cycle (the use of additional methods of contraception is required).

If one pill is missed during the first two weeks of the cycle, the next day you must take 2 tablets and continue taking it using additional methods of contraception until the end of the cycle.

If a pill is missed in the third week of the cycle, you should take it and continue taking Novinet without a 7-day break in this cycle. Since the estrogen content is minimal, if you miss the next dose, the risk of spotting and/or ovulation increases, so the use of additional methods of contraception is mandatory.

If vomiting or diarrhea occurs immediately after taking another Novinet tablet, the absorption process may be incomplete. If the stomach upset subsides within 12 hours, you should take an additional tablet and continue your usual contraceptive regimen. If the duration of vomiting or diarrhea exceeds 12 hours, the woman must use barrier methods of contraception during the period of illness and for the next 7 days.

Side effects

Reproductive system: amenorrhea during drug withdrawal, vaginal spotting or acyclic bleeding, changes in the state of vaginal mucus, candidiasis, development of vaginal inflammation, galactorrhea, pain, tension, enlarged mammary glands;
Nervous system: headache, mood instability, depression, migraine;
Digestive system: nausea, vomiting, ulcerative colitis, Crohn's disease, exacerbation or development of jaundice and/or itching caused by cholestasis, cholelithiasis;
Metabolism: increased body weight, fluid retention in the body, decreased tolerance to carbohydrates;
Organ of vision: in patients with contact lenses – increased sensitivity of the cornea;
Dermatological reactions: rash, erythema nodosum, chloasma, exudative erythema;
Other: development of allergic reactions.

The use of the drug may cause side effects that require immediate discontinuation of the drug:

Cardiovascular system: arterial hypertension; rarely - venous and arterial thromboembolism (including pulmonary embolism, stroke, myocardial infarction, deep vein thrombosis of the legs); very rarely - venous or arterial thromboembolism of the renal, hepatic, mesenteric, retinal veins and arteries;
Sense organs: hearing loss caused by otosclerosis;
Other: porphyria, hemolytic-uremic syndrome; rarely - exacerbation of reactive systemic lupus erythematosus; very rarely - transient Sydenham chorea.

Overdose

According to the instructions, Novinet in high doses can cause symptoms such as nausea and vomiting, as well as spotting from the vagina in girls. The drug does not have a specific antidote, so symptomatic treatment is prescribed. If signs of overdose are observed in the first 2-3 hours after taking the tablets, gastric lavage may be effective.

special instructions

Novinet is a reliable means of hormonal contraception.

The use of the drug should begin after a complete general medical and gynecological examination, including a detailed personal and family history, laboratory tests, blood pressure measurement, examination of the pelvic organs, mammary glands, and cytological analysis of a cervical smear. The gynecologist’s conclusion on the possibility of using the drug is made based on the data obtained. Having informed the patient about the possible negative effects and benefits of hormonal contraception, the doctor gives her the right to make the final decision.

The use of the drug should be carried out with regular (once every 6 months) examination by a gynecologist and careful individual monitoring of health status. A woman should know that the reason for immediate discontinuation of the drug is the appearance of one of the following abnormalities:

Diseases or conditions that contribute to the development of renal, cardiovascular failure;
Abnormalities in laboratory tests assessing liver function;
Pathologies of the hemostatic system;
Migraine;
Epilepsy;
Threat of developing estrogen-dependent gynecological diseases or estrogen-dependent neoplasms;
Severe depression (it is recommended to take vitamin B6 to correct the condition associated with the pathology of tryptophan metabolism);
Diabetes mellitus without vascular complications;
Sickle cell anemia.

While taking oral hormonal contraceptives, the risk of developing venous and arterial thromboembolic pathologies increases, especially in older women or with a family history of thromboembolic diseases (parents, sister, brother). The risk increases with heavy smoking, dyslipoproteinemia, obesity, diabetes mellitus with vascular lesions, heart valve disease with hemodynamic disturbances, arterial hypertension, atrial fibrillation, during prolonged immobilization associated with major surgery (including surgery on the lower extremities) or after severe trauma. .

The use of the contraceptive should be stopped 4 weeks before planned surgery and resumed 2 weeks after remobilization.

After childbirth, the likelihood of venous thromboembolic disease increases.

Diabetes mellitus, hemolytic-uremic syndrome, systemic lupus erythematosus, Crohn's disease, sickle cell anemia, ulcerative colitis increase the risk of developing venous thromboembolic diseases.

With a deficiency of proteins C and S, resistance to activated protein C, hyperhomocysteinemia, the presence of antiphospholipid antibodies, and a lack of antithrombin III, the likelihood of developing venous or arterial thromboembolic pathologies increases.

Targeted therapy of the above conditions helps reduce the risk of thromboembolism with characteristic symptoms such as sudden chest pain radiating to the left arm, sudden shortness of breath, unusually severe headache that continues for a long time (especially if the headache appears for the first time in combination with dizziness, weakness, acute abdomen, partial or complete loss of vision, diplopia, aphasia, focal epilepsy, collapse, movement disorders, numbness of half the body, severe unilateral pain in the calf muscle).

Taking a contraceptive can be regarded as one of many risk factors for developing breast cancer.

Long-term use of the drug may result in the development of benign or malignant liver tumors. This should be taken into account in the differential diagnostic assessment of abdominal pain, which may be associated with intraperitoneal bleeding or an increase in liver size.

Women who have a history of this pathology during pregnancy are at risk of developing chloasma, so they are advised to avoid direct sunlight or ultraviolet radiation.

The effectiveness of oral contraception may be affected by the simultaneous use of other drugs, in which case the use of additional barrier contraceptive methods is required.

The effect of the drug is reduced due to irregular, spotting or breakthrough bleeding that appears after several months of contraception. In this case, it is necessary to continue taking the pills until the end of the next cycle and in the absence of menstrual-like bleeding during the 7-day break or continuation of acyclic bleeding, stop taking the pills until pregnancy is ruled out.

In addition, skipping a pill, vomiting or diarrhea can interfere with the effect of the drug.

The action of the tablets can cause changes in laboratory parameters of kidney function, adrenal glands, liver, thyroid gland, levels of transport proteins and lipoproteins, and hemostasis indicators.

After acute viral hepatitis, use of the drug can be started after complete restoration of liver function (6 months or more).

Novinet does not protect against sexually transmitted diseases, including HIV infection (AIDS).

The effect of the drug on the ability to drive vehicles and machines has not been studied.

For impaired renal function

In case of renal failure (including a history), Novinet is prescribed with caution and only after a careful assessment of the balance of harm and benefit.

For liver dysfunction

The drug should not be prescribed for hepatitis (including a history of hepatitis, until laboratory and functional parameters are normalized and for 3 months after their normalization), cholestatic jaundice (including those accompanying pregnancy) and severe liver dysfunction. The contraceptive is used with caution in acute and chronic liver diseases.

Use in old age

Since Novinet is a contraceptive drug, it is not used in elderly patients.

Drug interactions

Concomitant use of Novinet with drugs that induce liver enzymes (barbiturates, hydantoin, primidone, rifampicin, carbamazepine, oxcarbazepine, felbamate, St. John's wort, topiramate, griseofulvin) reduces the effectiveness of contraception and increases the risk of breakthrough bleeding. It should be borne in mind that the maximum degree of induction of any of these drugs is achieved after 2-3 weeks of use, but can last up to 4 weeks after discontinuation of the drug.

Since tetracycline and ampicillin reduce the effectiveness of the drug, it is necessary to use additional barrier methods of contraception when combined with Novinet during the entire period of therapy and 7 (for rifampicin - 28) days after their discontinuation.

There may be a decrease in carbohydrate tolerance and an increased need for oral antidiabetic agents or insulin.

Analogs

Analogues of Novinet are: Marvelon, Regulon, Mercilon, Tri-Mercy.

Terms and conditions of storage

Store at 15-30 °C. Keep away from children.

Shelf life – 3 years.

Novinet (ethinyl estradiol + desogestrel) is a combined tablet contraceptive from the Hungarian pharmaceutical company GEDEON RICHTER. According to statistics, about 40% of women do not use pharmacological contraception. Meanwhile, from the point of view of embryology, human life begins with the fusion of the germ cells of a woman and a man, resulting in the formation of a nucleus containing unique genetic material. And this new human organism genetically can in no way be considered an alien (i.e. maternal) part of the body. Thus, abortion should be considered the deliberate taking of the life of a new biological individual. Combined pill contraceptives have been used for several decades. Progestogens of the first two generations do not have the proper level of selectivity of action. In addition, they are characterized by a number of undesirable side reactions, incl. arterial hypertension, deterioration of lipid profile and insulin resistance. Desogestrel does not have the above disadvantages. This substance is one of the components of the drug Novinet. The estrogenic component in the drug is ethinyl estradiol. Desogestrel is a 3rd generation progestogen. It has high (more than 80% bioavailability). It undergoes metabolic transformations in the liver with the formation of an active derivative - 3-ketodesogestrel. Desogestrel exhibits the greatest degree of selectivity towards progesterone receptors, which determines its powerful gestagenic effect.

At the same time, its androgenic and estrogenic effect is practically not manifested. Among all currently known progestogens, desogestrel has the highest selectivity index. Novine improves the lipid profile: it increases the level of “good” cholesterol in the blood - high-density lipoproteins, without affecting the level of low-density lipoproteins. When using Novinet, blood loss during menstruation is significantly reduced, and the condition of the skin improves, especially in the presence of acne. The effectiveness of Novinet as a contraceptive is associated with its ability to suppress the functioning of the ovaries, including the formation of follicles. From this point of view, Novinet is one of the best contraceptives. The incidence of side effects when taking this contraceptive is relatively low. This usually happens during the first three months of pharmacotherapy, when the body adapts to functioning in new conditions. At the same time, side effects do not pose any threat to the health and well-being of the patient and disappear almost completely by the fourth cycle of contraceptive pharmacotherapy. A side effect characteristic of tablet contraceptives - weight gain - in the case of Novinet appears much less frequently. The drug has very little effect on hemodynamics in the peripheral vascular bed, and therefore does not have a pronounced effect on blood pressure levels.

Pharmacology

A monophasic hormonal contraceptive for oral administration containing a combination of estrogen (ethinyl estradiol) and a progestin (desogestrel). The main contraceptive effect is to inhibit gonadotropins and suppress ovulation. In addition, by increasing the viscosity of the cervical fluid, the movement of sperm through the cervical canal slows down, and changes in the condition of the endometrium prevent the implantation of a fertilized egg.

Ethinyl estradiol is a synthetic analogue of the follicular hormone estradiol.

Desogestrel has a pronounced gestagenic and antiestrogenic effect, similar to endogenous progesterone, and weak androgenic and anabolic activity.

The drug has a beneficial effect on lipid metabolism: it increases the HDL content in plasma without affecting the LDL content.

When taking the drug, the loss of menstrual blood is significantly reduced (in case of initial menorrhagia), the menstrual cycle is normalized, and a beneficial effect on the skin is noted, especially in the presence of acne vulgaris.

Pharmacokinetics

Desogestrel

Suction

Desogestrel is quickly and almost completely absorbed from the gastrointestinal tract and metabolized into 3-keto-desogestrel, which is a biologically active metabolite of desogestrel.

Cmax is reached after 1.5 hours and is 2 ng/ml. Bioavailability - 62-81%.

Distribution

3-keto-desogestrel binds to plasma proteins, mainly albumin and sex hormone binding globulin (SHBG).

V d is 1.5 l/kg. C ss is established by the second half of the menstrual cycle, when the level of 3-keto-desogestrel increases 2-3 times.

Metabolism

In addition to 3-keto-desogestrel (which is formed in the liver and in the intestinal wall), other metabolites are formed: 3α-OH-desogestrel, 3β-OH-desogestrel, 3α-OH-5α-H-desogestrel (first phase metabolites). These metabolites do not have pharmacological activity and are partially converted, through conjugation (the second phase of metabolism), into polar metabolites - sulfates and glucuronates. Clearance from blood plasma is about 2 ml/min/kg body weight.

Removal

T1/2 is 30 hours. Metabolites are excreted in the urine and feces (in a ratio of 4:6).

Ethinyl estradiol

Suction

Ethinyl estradiol is quickly and completely absorbed from the gastrointestinal tract. Cmax is achieved 1-2 hours after taking the drug and is 80 pg/ml. The bioavailability of the drug due to presystemic conjugation and the “first pass” effect through the liver is about 60%.

Distribution

Ethinyl estradiol is completely bound to plasma proteins, mainly albumin.

Vd is 5 l/kg. C ss is established by the 3-4th day of administration, while the level of ethinyl estradiol in the serum is 30-40% higher than after a single dose of the drug.

Metabolism

Presystemic conjugation of ethinyl estradiol is significant. Bypassing the intestinal wall (first phase of metabolism), it undergoes conjugation in the liver (second phase of metabolism). Ethinyl estradiol and its conjugates of the first phase of metabolism (sulfates and glucuronides) are excreted into bile and enter the enterohepatic circulation. Clearance from blood plasma is about 5 ml/min/kg body weight.

Removal

T1/2 of ethinyl estradiol averages about 24 hours. About 40% is excreted in the urine and about 60% in feces.

Release form

Light yellow, round, biconvex, film-coated tablets, marked “P9” on one side and “RG” on the other.

Excipients: quinoline yellow dye (E104), α-tocopherol, magnesium stearate, colloidal silicon dioxide, stearic acid, povidone, potato starch, lactose monohydrate.

Film shell composition: propylene glycol, macrogol 6000, hypromellose.

21 pcs. - blisters (1) - cardboard packs.
21 pcs. - blisters (3) - cardboard packs.

Dosage

The drug is prescribed orally.

Taking pills starts on the 1st day of the menstrual cycle. Prescribe 1 tablet/day for 21 days, if possible at the same time of day. After taking the last tablet from the package, take a 7-day break, during which menstrual-like bleeding occurs due to drug withdrawal. The next day after a 7-day break (4 weeks after taking the first tablet, on the same day of the week), resume taking the drug from the next package, also containing 21 tablets, even if the bleeding has not stopped. This pill regimen is followed as long as there is a need for contraception. If you follow the rules of administration, the contraceptive effect remains during the 7-day break.

First dose of the drug

The first tablet should be taken on the first day of the menstrual cycle. In this case, it is not necessary to use additional methods of contraception. You can start taking pills from the 2-5th day of menstruation, but in this case, in the first cycle of using the drug, you must use additional methods of contraception in the first 7 days of taking the pills.

If more than 5 days have passed since the start of menstruation, you should delay starting the drug until your next menstruation.

Taking the drug after childbirth

Women who are not breastfeeding can start taking the pill no earlier than 21 days after giving birth, after consulting with their doctor. In this case, there is no need to use other methods of contraception. If there has already been sexual contact after childbirth, then taking the pills should be postponed until the first menstruation. If a decision is made to take the drug later than 21 days after birth, then additional methods of contraception must be used in the first 7 days.

Taking the drug after an abortion

After an abortion, in the absence of contraindications, you should start taking pills from the first day after surgery, and in this case there is no need to use additional methods of contraception.

Switching from another oral contraceptive

After using another hormonal oral contraceptive containing 30 mcg ethinyl estradiol, according to a 21-day regimen, it is recommended to take the first Novinet tablet the day after completing the course of the previous drug. There is no need to take a 7-day break or wait for the start of menstruation. There is no need to use additional methods of contraception.

When switching from a drug containing 28 tablets, the day after the tablets in the package run out, you should start a new package of Novinet ® .

Switching to Novinet after using oral hormonal drugs containing only progestogen ("mini-pill")

The first Novinet ® tablet should be taken on the 1st day of the cycle. There is no need to use additional methods of contraception.

If menstruation does not occur while taking the mini-pill, then after excluding pregnancy, you can start taking Novinet on any day of the cycle, but in this case, in the first 7 days it is necessary to use additional methods of contraception (using a cervical cap with spermicidal gel, a condom, or abstinence from sexual intercourse). The use of the calendar method in these cases is not recommended.

Delay of the menstrual cycle

If there is a need to delay menstruation, you must continue taking the tablets from the new package, without a 7-day break, according to the usual regimen. When menstruation is delayed, breakthrough or spotting bleeding may occur, but this does not reduce the contraceptive effect of the drug. Regular use of Novinet can be resumed after the usual 7-day break.

Missed pills

If a woman forgot to take a pill on time, and no more than 12 hours have passed since the omission, she needs to take the forgotten pill, and then continue taking it at the usual time. If more than 12 hours have passed between taking pills, this is considered a missed pill; the reliability of contraception in this cycle is not guaranteed and the use of additional methods of contraception is recommended.

If you miss one tablet in the first or second week of the cycle, you need to take 2 tablets. the next day and then continue regular use using additional methods of contraception until the end of the cycle.

If you miss a pill in the third week of the cycle, you should take the forgotten pill, continue taking it regularly and not take a 7-day break. It is important to remember that due to the minimum dose of estrogen, the risk of ovulation and/or spotting increases if you miss a pill and therefore the use of additional methods of contraception is recommended.

Vomiting/diarrhea

If vomiting or diarrhea occurs after taking the drug, then absorption of the drug may be inadequate. If the symptoms stop within 12 hours, then you need to take one more tablet. After this, you should continue taking the tablets as usual. If vomiting or diarrhea continues for more than 12 hours, then it is necessary to use additional methods of contraception during vomiting or diarrhea and for the next 7 days.

Overdose

Symptoms: nausea, vomiting, in girls - bleeding from the vagina.

Treatment: in the first 2-3 hours after taking the drug in a high dose, gastric lavage is recommended. There is no specific antidote, treatment is symptomatic.

Interaction

Medicines that induce liver enzymes, such as hydantoin, barbiturates, primidone, carbamazepine, rifampicin, oxcarbazepine, topiramate, felbamate, griseofulvin, St. John's wort preparations, reduce the effectiveness of oral contraceptives and increase the risk of breakthrough bleeding. The maximum level of induction is usually achieved no earlier than 2-3 weeks, but can last up to 4 weeks after discontinuation of the drug.

Ampicillin and tetracycline reduce the effectiveness of Novinet (the mechanism of interaction has not been established). If co-administration is necessary, it is recommended to use an additional barrier method of contraception throughout the entire course of treatment and for 7 days (for rifampicin - within 28 days) after discontinuation of the drug.

Oral contraceptives may decrease carbohydrate tolerance and increase the need for insulin or oral antidiabetic agents.

Side effects

Side effects requiring discontinuation of the drug

From the cardiovascular system: arterial hypertension; rarely - arterial and venous thromboembolism (including myocardial infarction, stroke, deep vein thrombosis of the lower extremities, pulmonary embolism); very rarely - arterial or venous thromboembolism of the hepatic, mesenteric, renal, retinal arteries and veins.

From the senses: hearing loss caused by otosclerosis.

Other: hemolytic-uremic syndrome, porphyria; rarely - exacerbation of reactive systemic lupus erythematosus; very rarely - Sydenham's chorea (passing after discontinuation of the drug).

Other side effects are more common but less severe. The advisability of continuing to use the drug is decided individually after consultation with a doctor, based on the benefit/risk ratio.

From the reproductive system: acyclic bleeding/bloody discharge from the vagina, amenorrhea after discontinuation of the drug, changes in the state of vaginal mucus, the development of inflammatory processes in the vagina, candidiasis, tension, pain, enlarged mammary glands, galactorrhea.

From the digestive system: nausea, vomiting, Crohn's disease, ulcerative colitis, the occurrence or exacerbation of jaundice and/or itching associated with cholestasis, cholelithiasis.

Dermatological reactions: erythema nodosum, exudative erythema, rash, chloasma.

From the central nervous system: headache, migraine, mood lability, depression.

On the part of the organ of vision: increased sensitivity of the cornea (when wearing contact lenses).

Metabolism: fluid retention in the body, change (increase) in body weight, decreased tolerance to carbohydrates.

Other: allergic reactions.

Indications

Contraception.

Contraindications

the presence of severe and/or multiple risk factors for venous or arterial thrombosis (including severe or moderate arterial hypertension with blood pressure ≥ 160/100 mm Hg);
presence or indication in history of precursors of thrombosis (including transient ischemic attack, angina pectoris);
migraine with focal neurological symptoms, incl. in the anamnesis;
venous or arterial thrombosis/thromboembolism (including myocardial infarction, stroke, deep vein thrombosis of the leg, pulmonary embolism) currently or in history;
a history of venous thromboembolism;
diabetes mellitus (with angiopathy);
pancreatitis (including a history), accompanied by severe hypertriglyceridemia;
dyslipidemia;
severe liver diseases, cholestatic jaundice (including during pregnancy), hepatitis, incl. history (before normalization of functional and laboratory parameters and within 3 months after their normalization);
jaundice when taking GCS;
gallstone disease currently or in history;
Gilbert's syndrome, Dubin-Johnson syndrome, Rotor syndrome;
liver tumors (including history);
severe itching, otosclerosis or its progression during a previous pregnancy or taking corticosteroids;
hormone-dependent malignant neoplasms of the genital organs and mammary glands (including if they are suspected);
vaginal bleeding of unknown etiology;
smoking over the age of 35 (more than 15 cigarettes per day);
pregnancy or suspicion of it;
lactation period;
hypersensitivity to the components of the drug.

The drug should be prescribed with caution in conditions that increase the risk of developing venous or arterial thrombosis/thromboembolism: age over 35 years, smoking, family history, obesity (body mass index more than 30 kg/m2), dyslipoproteinemia, arterial hypertension, migraine, epilepsy, valvular heart defects, atrial fibrillation, prolonged immobilization, extensive surgery, surgery on the lower extremities, severe trauma, varicose veins and superficial thrombophlebitis, the postpartum period, the presence of severe depression (including a history), changes in biochemical parameters ( activated protein C resistance, hyperhomocysteinemia, antithrombin III deficiency, protein C or S deficiency, antiphospholipid antibodies, including antibodies to cardiolipin, lupus anticoagulant), diabetes mellitus not complicated by vascular disorders, SLE, Crohn's disease, ulcerative colitis, sickle disease -cellular anemia, hypertriglyceridemia (including family history), acute and chronic liver diseases.

Features of application

Use during pregnancy and breastfeeding

Novinet ® is contraindicated for use during pregnancy and lactation (breastfeeding).

Use for liver dysfunction

Contraindicated in severe liver diseases, cholestatic jaundice (including during pregnancy), hepatitis, incl. history (before normalization of functional and laboratory parameters and within 3 months after their normalization). The drug should be prescribed with caution for acute and chronic liver diseases.

Use for renal impairment

With caution and only after a thorough assessment of the benefits and risks of use, the drug should be prescribed for renal failure (including a history),

special instructions

Before starting to use the drug, it is necessary to conduct a general medical examination (detailed family and personal history, blood pressure measurement, laboratory tests) and gynecological examination (including examination of the mammary glands, pelvic organs, cytological analysis of a cervical smear). Such examinations during the period of taking the drug are carried out regularly, every 6 months.

The drug is a reliable contraceptive: the Pearl index (an indicator of the number of pregnancies occurring during the use of a contraceptive method in 100 women over 1 year) when used correctly is about 0.05.

In each case, before prescribing hormonal contraceptives, the benefits or possible negative effects of their use are individually assessed. This issue must be discussed with the patient, who, after receiving the necessary information, will make the final decision on the preference for hormonal or any other method of contraception.

The woman's health condition must be carefully monitored. If any of the following conditions/diseases appear or worsen while taking the drug, you must stop taking the drug and switch to another, non-hormonal method of contraception:

diseases of the hemostatic system;
conditions/diseases predisposing to the development of cardiovascular and renal failure;
epilepsy;
migraine;
the risk of developing an estrogen-dependent tumor or estrogen-dependent gynecological diseases;
diabetes mellitus not complicated by vascular disorders;
severe depression (if depression is associated with a violation of tryptophan metabolism, then vitamin B 6 can be used for correction);
sickle cell anemia, because in some cases (for example, infections, hypoxia), estrogen-containing drugs for this pathology can provoke thromboembolism;
the appearance of abnormalities in laboratory tests assessing liver function.

Thromboembolic diseases

Epidemiological studies have shown that there is a connection between taking oral hormonal contraceptives and an increased risk of developing arterial and venous thromboembolic diseases (including myocardial infarction, stroke, deep vein thrombosis of the lower extremities, pulmonary embolism). An increased risk of venous thromboembolic diseases has been proven, but it is significantly less than during pregnancy (60 cases per 100 thousand pregnancies). When using oral contraceptives, arterial or venous thromboembolism of the hepatic, mesenteric, renal or retinal vessels is very rarely observed.

The risk of arterial or venous thromboembolic disease increases:

with age;
when smoking (heavy smoking and age over 35 years are risk factors);
if there is a family history of thromboembolic diseases (for example, parents, brother or sister). If a genetic predisposition is suspected, it is necessary to consult a specialist before using the drug;
for obesity (body mass index more than 30 kg/m2);
with dislipoproteinemia;
with arterial hypertension;
for diseases of the heart valves complicated by hemodynamic disorders;
with atrial fibrillation;
with diabetes mellitus complicated by vascular lesions;
with prolonged immobilization, after major surgery, after surgery on the lower extremities, after severe trauma.

In these cases, it is assumed to temporarily stop using the drug (no later than 4 weeks before surgery, and resume no earlier than 2 weeks after remobilization).

Women after childbirth have an increased risk of venous thromboembolic disease.

It should be taken into account that diabetes mellitus, systemic lupus erythematosus, hemolytic-uremic syndrome, Crohn's disease, ulcerative colitis, and sickle cell anemia increase the risk of developing venous thromboembolic diseases.

It should be taken into account that resistance to activated protein C, hyperhomocysteinemia, protein C and S deficiency, antithrombin III deficiency, and the presence of antiphospholipid antibodies increase the risk of developing arterial or venous thromboembolic diseases.

When assessing the benefit/risk ratio of taking the drug, it should be taken into account that targeted treatment of this condition reduces the risk of thromboembolism. Symptoms of thromboembolism are:

sudden chest pain that radiates to the left arm;
sudden shortness of breath;
any unusually severe headache that continues for a long time or appears for the first time, especially when combined with sudden complete or partial loss of vision or diplopia, aphasia, dizziness, collapse, focal epilepsy, weakness or severe numbness of half the body, movement disorders, severe unilateral pain in the calf muscle, acute abdomen.

Tumor diseases

Some studies have reported an increased incidence of cervical cancer in women who took hormonal contraceptives for a long time, but the results of the studies are inconsistent. Sexual behavior, infection with the human papillomavirus and other factors play a significant role in the development of cervical cancer.

A meta-analysis of 54 epidemiological studies found that there is a relative increase in the risk of breast cancer among women taking oral hormonal contraceptives, but the higher detection rate of breast cancer may have been associated with more regular medical screening. Breast cancer is rare among women under 40, whether they take hormonal birth control or not, and increases with age. Taking pills can be considered one of many risk factors. However, the woman should be made aware of the possible risk of developing breast cancer based on an assessment of the benefit-risk ratio (protection against ovarian and endometrial cancer).

There are few reports of the development of benign or malignant liver tumors in women taking hormonal contraceptives for a long time. This should be kept in mind when differentially assessing abdominal pain, which may be associated with an increase in liver size or intraperitoneal bleeding.

Chloasma can develop in women with a history of this disease during pregnancy. Those women who are at risk of developing chloasma should avoid contact with sunlight or ultraviolet radiation while taking Novinet.

Efficiency

The effectiveness of the drug may be reduced in the following cases: missed pills, vomiting and diarrhea, simultaneous use of other drugs that reduce the effectiveness of birth control pills.

If the patient is concomitantly taking another drug that may reduce the effectiveness of birth control pills, additional methods of contraception should be used.

The effectiveness of the drug may decrease if, after several months of their use, irregular, spotting or breakthrough bleeding appears, in such cases it is advisable to continue taking the tablets until they run out in the next package. If at the end of the second cycle menstrual-like bleeding does not begin or acyclic bleeding does not stop, stop taking the pills and resume it only after pregnancy has been ruled out.

Changes in laboratory parameters

Under the influence of oral contraceptive pills - due to the estrogen component - the level of some laboratory parameters (functional indicators of the liver, kidneys, adrenal glands, thyroid gland, hemostasis indicators, levels of lipoproteins and transport proteins) may change.

Additional Information

After acute viral hepatitis, the drug should be taken after normalization of liver function (no earlier than 6 months).

With diarrhea or intestinal disorders, vomiting, the contraceptive effect may be reduced. While continuing to take the drug, it is necessary to use additional non-hormonal methods of contraception.

Women who smoke have an increased risk of developing vascular diseases with serious consequences (myocardial infarction, stroke). The risk depends on age (especially in women over 35 years of age) and on the number of cigarettes smoked.

The woman should be warned that the drug does not protect against HIV infection (AIDS) and other sexually transmitted diseases.

Impact on the ability to drive vehicles and operate machinery

No studies have been conducted to study the effect of Novineta on the abilities necessary to drive a car and operate machinery.

Contraception in women is significantly different at age 40 than at age 25. Reproductive health declines over time after age 40. The ovaries still continue to produce hormones (estrogen and progesterone), but in significantly small quantities. This completely begins to rebuild the body, which makes it more difficult to conceive a child during such a period. To maintain the activity of the ovaries and avoid the formation of diseases of the genital area, doctors have invented a special contraception. For this purpose, there is a drug - Novinet for women after 40 years.

Compound

Active components:

Ethinyl estradiol - 0.020 mg;
Desogestrel - 0.150 mg.

Additional components:

Quinoline yellow dye E 104;
Magnesium stearate;
Stearic acid;
Potato starch;
Lactose monohydrate.

Upper layer:

Propylene glycol;
Macrogol 6000;
Pipromellose.

Description

The convex tablets are round in shape and have a pale yellow color.

pharmachologic effect

The effect of the drug is that the active components inhibit the maturation of the egg.
Before starting to use Novinet, it is necessary to carry out a uniform and gynecological examination to exclude diseases that may pose a threat when using hormonal drugs.
When taking the drug, you should constantly undergo medical monitoring every 6 months.

Indications for use

Novinet is used to achieve a contraceptive effect.

Contraindications

The drug has the following contraindications:

Serious risk factors for venous or arterial thrombosis;
Headaches of a neurological nature, including past illnesses;
Thrombophlebitis and other diseases of blood vessels and heart (heart attack, stroke, blockage of deep veins, thromboembolism) in the current period, including past illnesses;
Diabetes;
Pancreatitis (should be considered even if pancreatitis was in the past);
The formation of chronic atherosclerosis, which is characterized by hardening and narrowing of blood vessels;
Liver diseases, jaundice, hepatitis (until all characteristics return to normal values);
Formation of gallstones;
Benign and malignant liver tumors (including past diseases);
Irritation, itching, otosclerosis;
Vaginal bleeding of unknown cause;
Tobacco smoking over 35 years of age (more than 15 cigarettes per day);
Lactation;
High susceptibility of the body to the components of Novinet.

Novinet tablets: instructions for use

It is necessary to take Novinet on the 1st day of critical days. The prescription is 1 tablet, taken once a day for 3 weeks, it is better if taken at the same time every day. When the last pill is taken on the 21st day, you need to take a week-long break. As a rule, critical days begin during this period of time. After a week, you need to start taking the pills again, even when menstruation has not stopped. A similar regimen for taking the drug should be followed as long as there is a need for a contraceptive result. If you follow the instructions and recommendations, the contraceptive result will last even with a 7-day pause.

First dose of the drug

The first tablet must be used from the first day of the monthly cycle. In this situation, there is no need to use auxiliary methods of protecting sexual contact. It is possible to delay the start of use by 2-5 days of the menstrual cycle, but in such situations it will be necessary to use auxiliary methods to protect sexual intercourse throughout the week.

If more than 5 days have passed from the beginning of the critical days, it is necessary to reschedule the intake of Novinet until the onset of the subsequent menstrual process.

Taking the drug after childbirth

What you need to pay attention to right away is that taking pills during lactation is prohibited. However, if the period of breastfeeding has already passed or has not yet begun, you are allowed to take the pills no earlier than three weeks after birth, after consulting with your doctor in advance. In such circumstances, there is no need to use other methods of protecting sexual intercourse. If you had sexual intercourse after childbirth, then taking the drug should be delayed until the onset of menstruation.

Taking the drug after an abortion

After the operation, if there are no contraindications, you should start taking Novinet immediately after the first day after the abortion. In this situation, there is no need to use auxiliary methods of protecting sexual contact.

Switching from another contraceptive

After using another hormonal contraceptive, according to a three-week use regimen, the first dose of Novinet is recommended to be taken the next day after the end of taking the previous drug. There is no need to wait a week to stop taking the pills. There is no need to use auxiliary contraception.
If you plan to switch from a drug that contains 28 tablets, then you should start taking the new drug immediately the next day after finishing the previous one.

The Novinet tablet must be taken at the onset of menstruation. It is not necessary to use auxiliary methods of protecting sexual contact.

If after using the Mini-Pill there are no menstrual days, then research is required to exclude a possible pregnancy. After this, it is allowed to use the drug on any day of the menstrual cycle, but additional protection of sexual contact should be carried out throughout the week.

Delayed menstrual cycle

If there is a need to delay critical days, you need to extend Novinet from the next pack, without a weekly break. When the critical days are delayed, breakthrough or spotting bleeding may occur. However, this does not reduce the contraceptive effect. Systematic use of Novinet can be resumed after an ordinary one-week break.

Missed pills

If you miss a pill and no more than 12 hours have passed, you need to take the missed pill and then continue taking the pills as usual. If more than 12 hours have passed between taking pills, this is a missed pill; the safety of sexual intercourse in this case will not be ensured and the use of auxiliary methods of protection is recommended.

If a tablet is missed in the 1st or 2nd week of the cycle, you should take 2 tablets on the next day and then continue according to the usual regimen, using auxiliary methods of protection until the end of the cycle.

If a pill is missed in the 3rd week of the cycle, you should take the forgotten pill and continue systematically. At the same time, do not take a week-long break.

Vomiting and diarrhea

There are situations when vomiting or stomach upset may occur while taking the drug. In such situations, the absorption of the drug by the body may be defective. If signs of vomiting and diarrhea disappear after 12 hours, then you should take another tablet. Then you need to take the pills according to the schedule. If vomiting or diarrhea continues for more than 12 hours, auxiliary methods of protection should be used during the period of vomiting or diarrhea and in the next 7 days.

Side effects

Heart and vascular system: persistent increase in blood pressure; uncommon – thromboembolism (including heart attack, stroke);
Sense organs: hearing loss, which is explained by the formation of otosclerosis.
Reproductive system: non-periodic vaginal menorrhagia or spotting, absence of menstruation after discontinuation of Novinet, change in vaginal mucus, formation of inflammatory flows in the vagina, candidiasis, pain.
Digestive tract: vomiting, formation or worsening of jaundice.
Skin reactions: Erythema nodosum, irritation, hyperpigmentation of the skin of the face.
Nervous system: changes in emotional state.
Organs of vision: increased sensitivity of the cornea (if contact lenses are worn).
Metabolism: slower removal of fluid from the body, change (increase) in weight.
Other: Allergic reactions may occur; lupus erythematosus is rarely worsened.
Other minor manifestations may occur more frequently, but are less severe. The rationality of continuing to use the product is decided personally after consultation with a doctor, based on the benefits and risks for the person.

Analogs

Based on the identity of the active substance, the following analogues are distinguished:

Regulon.
Marvelon.
Mercilon.

Price in pharmacies

The average cost of Novinet at pharmaceutical points in Moscow is 450 rubles.

International name

Ethinylestradiol+Desogestrel

Group affiliation

Contraceptive

Dosage form

Tablets, film-coated tablets

pharmachologic effect

Contraceptive drug. Inhibits the pituitary secretion of gonadotropic hormones. The contraceptive effect is due to the effect on the hypothalamic-pituitary-ovarian system. Ethinyl estradiol is a synthetic analogue of the follicular hormone estradiol, which participates together with the corpus luteum hormone in the menstrual cycle. A progestin drug (desogestrel) inhibits the synthesis of LH and FSH by the pituitary gland (preventing follicle maturation), etc. blocks ovulation. Along with the indicated central and peripheral mechanisms that prevent the maturation of an egg capable of fertilization, the contraceptive effect is due to a decrease in the susceptibility of the endometrium to the blastocyst, as well as an increase in the viscosity of the mucus located in the cervix, which makes it relatively impenetrable for sperm.

It has a beneficial effect on lipid metabolism: it increases the concentration of HDL in plasma without affecting the content of LDL. During treatment, there is a significant decrease in the amount of blood lost (with initial menorrhagia). It has a beneficial effect on the skin, especially improving its condition in cases of acne vulgaris; when taken regularly, it also has a therapeutic effect, normalizing the menstrual cycle and helping to prevent the development of a number of gynecological diseases, incl. tumor nature.

Indications

Contraception.

Contraindications

Hypersensitivity, pregnancy, liver failure, congenital hyperbilirubinemia (Gilbert, Dubin-Johnson and Rotor syndromes), liver tumors (hemangioma, liver cancer), thromboembolism (including a history and an increased risk of its development), cerebrovascular accidents (ischemic stroke, hemorrhagic stroke), ischemic heart disease, arterial hypertension (severe forms), atherosclerosis, decompensated heart defects, myocarditis, diabetes mellitus, retinopathy, angiopathy, sickle cell anemia, breast and endometrial cancer, endometrial hyperplasia, endometriosis, breast fibroadenoma, metrorrhagia (of unclear etiology), lipid metabolism disorders, jaundice or itching during a former pregnancy, otosclerosis with worsening during pregnancy, porphyria, smoking women over 35 years of age.

Side effects

Headache, gastralgia, nausea, vomiting; soreness and engorgement of the mammary glands; weight gain, impaired glucose tolerance, fluid retention in the body, changes in libido, decreased mood, swelling of the eyelids, skin rash, erythema nodosum, conjunctivitis, discomfort when wearing contact lenses, impaired perception (visual impairment, hearing loss, flickering before the eyes ), thrombophlebitis, thromboembolism, generalized itching, cholestatic jaundice, cholelithiasis, increased blood pressure, intermenstrual bleeding, changes in vaginal secretion (possible development of vaginal candidiasis).

With long-term use (extremely rarely) - chloasma, hepatocellular adenoma.

Application and dosage

Orally, 1 tablet per day (starting no later than the 5th day of the cycle; 1st day of the cycle is 1st day of menstruation) daily, at the same time, without a break, for 21 days, then take a break for 7 days. In the first 14 days, additional contraceptive measures must be used.

If more than 5 days have passed since the start of menstruation, then taking the pills begins with the next cycle. After childbirth, the drug should be taken on the first day of the first independent menstruation. After a miscarriage or induced abortion, the drug must be taken immediately. The full contraceptive effect is maintained provided that the tablets are taken systematically (maximum delay is no more than 12 hours). If more time has passed, then the next day at the usual time you should take 2 tablets of the drug, but you must use additional contraception for the next 14 days or until the next menstruation occurs.

special instructions

Before starting and every 6 months of using the drug, a general medical and gynecological examination is recommended (including gynecological control, examination of the mammary glands, liver function, monitoring of blood pressure and cholesterol concentrations in the blood, urine analysis). It is a reliable contraceptive drug: Pearl index (the number of pregnancies that occurred during the use of a contraceptive method in 100 women over 1 year) – 0.05. Due to the fact that the contraceptive effect of the drug from the start of administration is fully manifested by the 14th day, in the first 2 weeks of treatment it is recommended to additionally use non-hormonal methods of contraception.

After acute viral hepatitis, it should be taken after normalization of liver function (no earlier than 6 months). In case of diarrhea or intestinal disorders, vomiting, the contraceptive effect may decrease (without stopping the drug, it is necessary to use additional non-hormonal methods of contraception). Women who smoke have an increased risk of developing vascular diseases with serious consequences (myocardial infarction, stroke). The risk depends on age (especially in women over 35 years of age) and on the number of cigarettes smoked. During lactation, milk secretion may decrease; small amounts are excreted in breast milk. Estrogen-containing drugs increase the risk of thrombosis in women who have undergone surgery or prolonged immobilization. Women who have chloasma should avoid sun exposure.

Interaction

Rifampicin, isoniazid, ampicillin, neomycin, penicillins, tetracycline, chloramphenicol, griseofulvin, barbiturates, carbamazepine, activated charcoal and laxatives reduce the effectiveness and contribute to the occurrence of “breakthrough” bleeding.

Reduces the effectiveness of oral anticoagulants, anxiolytics (diazepam), tricyclic antidepressants, theophylline, caffeine, hypoglycemic drugs, clofibrate, corticosteroids.

Reviews about the drug Novinet: 8

Catherine

Hello, I'm 20 years old. I took the pills for the first month on my own initiative and without consulting a doctor. After 21 days, my period started on the 3rd day. While taking the pills, my chest felt full and ached. How normal is this? Or is this a period of adaptation to the drug? I had never taken such contraceptives before.

Katerina

Hello, I’ve been taking Novinet for 2 weeks now. My period is over, but still some kind of spotting (brownish discharge) continues and my chest hurts. Almost 3 months ago I had a termination of pregnancy at 21 weeks. Tell me what could be the matter?

26 years old Saw and previously new, 3 years. I don’t remember what happened at the beginning, but at the end of the third year, I was already sick from the pills, very much, just in her mouth, and she immediately started to come back (((Now I’m taking 1 pack to move my periods a little (for the holidays) It’s just terrible, nausea, loss of appetite, spotting (sort of adaptation to the drug) and a very strong tug in the stomach! Thank God there are 4 tablets left and that’s ALL! Plus: it protects well, and I don’t gain weight!

I’ve been taking Novinet for a week, my period is over, but some kind of brown smudge is flowing, a constant feeling of nausea, weakness, blood pressure is fluctuating, in general it’s kind of a mess. If this is a side effect, when will it end? I stop taking this drug, it’s clearly not suitable.

I finish 1 package of Novinet, which has changed for the worse: libido has definitely decreased, muscle pain has appeared. limbs and cramps at night. For the better: PMS is less pronounced, i.e. I don’t feel any mood swings, my breasts are enlarged, but they don’t hurt. We’ll see how the first menstruation goes (before taking it, I was worried about their abundance).

Katerina 19 years old

I take 8 tablets. Every day my lower abdomen hurts. Today diarrhea started..and I don’t understand if it’s the pills or what.

Natalya, 01/27/2016, age: 40

I've been taking Novinet for almost 4 years now. Now nothing bothers me, I feel great, there is no nausea.

Write your review

Do you use Novinet as an analogue or vice versa its analogues?